ALNY — ALNYLAM PHARMACEUTICALS, INC.
Data coverage, completeness and provenance for ALNYLAM PHARMACEUTICALS, INC. in the Stock Market API — Health Care · Biotechnology.
Stored price coverage
Source date: 2026-11-19T21:00:01. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 147.8200 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 149.4000 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 156.5000 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 159.7300 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 165.0400 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/ALNY/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Employees: 2,500 · Website: https://www.alnylam.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/ALNY/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 30 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 29 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 29 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 29 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 29 | sec_edgar |
Get ALNY data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/ALNY
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/ALNY/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/ALNY/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/ALNY/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/ALNY
Query ALNY programmatically
Free tier — instant API key. Built for AI agents.
Other NASDAQ · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for ALNY?
- Stored coverage for ALNY: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/ALNY; inspect available source metadata for provenance.
- How complete is ALNY's financial data?
- The anchor reporting period (FY2025) has 94.1% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for ALNY?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/ALNY/financials.
- Where does ALNY's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/ALNY/financials; missing tags do not establish provenance.